AI-generated analysis. Always verify with the original filing.
NeuroOne Medical Technologies Corporation reported fiscal Q1 2026 financial results with product revenue of $2.9 million, net loss of $1.4 million or ($0.03) per share, and cash of $3.6 million as of December 31, 2025. The company expects at least $10.5 million in product revenue for fiscal year 2026 and highlighted FDA clearance for OneRF Trigeminal Nerve Ablation System with nine successful cases.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Secu
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated February 17, 2026 104 Cover Page Interactive Data File (embedd
| Metric | Value | Basis |
|---|---|---|
| Product Revenue | $2.90 | |
| Product Gross Profit | $1.60 | |
| Product Gross Margin | 54.2% | |
| Total Operating Expenses | $3.30 | |
| Research & Development Expense | $1.40 | |
| Selling, General & Administrative Expense | $1.90 | |
| Net Loss | $1.40 | |
| Net Loss per Share | $-0.03 |
Jason Mills
Effective: 2025-12